-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium
20 Dec 2019Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO
13 Dec 2019Immunicum AB (publ) Interim Report January – September 2019
06 Nov 2019
News
-
Immunicum Article in BioStock
13 Dec 2019 -
RedEye Interview with Michael Oredsson, Chairman of the Board
13 Dec 2019 -
Immunicum Article in BioStock
2 Dec 2019 -
Presentation at BioStock Life Science Summit
24 Oct 2019 -
Immunicum Article in BioStock
24 Oct 2019
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
